LTR Pharma (ASX: LTP) has signed an exclusive pilot commercialisation agreement with US pharmaceutical company Marius Pharmaceuticals to introduce Marius' KYZATREX oral testosterone capsules to the Australian market.

KYZATREX is FDA-approved and is commercially available in the United States, having received US regulatory approval in 2022. Initial stock has now arrived in Australia, with early patient access to be facilitated through the TGA Special Access Scheme (SAS), a pathway that allows Australian clinicians to supply unapproved therapeutic goods to individual patients outside of formal registration where clinical need exists. A pilot arrangement of this kind typically precedes any broader registration or full commercial rollout, which would require separate TGA processes.

Testosterone deficiency affects energy, mood, muscle mass, bone density and sexual function. The condition remains underdiagnosed and undertreated in Australia, where most replacement therapy is currently delivered by injection, gel, patch or implant. These existing delivery methods each carry practical drawbacks — injections require clinic attendance or self-administration schedules, while gels and patches can involve daily application and transfer concerns — which has long created interest in a practical oral option for testosterone therapy.

LTR Pharma executive chairman Lee Rodne said KYZATREX uses a proprietary formulation designed to facilitate lymphatic absorption, reducing the first-pass hepatic metabolism associated with earlier oral testosterone therapies. That hepatic burden was a key limitation of earlier oral testosterone products, historically associated with liver-related safety concerns that restricted their use. He added that KYZATREX is supported by clinical data demonstrating its ability to restore testosterone levels in men with testosterone deficiency.

"We are pleased to partner with Marius to introduce KYZATREX in Australia. As an FDA-approved oral testosterone therapy, KYZATREX represents a complementary opportunity to broaden our men's health portfolio by leveraging the clinical networks, telehealth channels and commercial infrastructure we have already established through SPONTAN," Mr Rodne said.

"At the same time, we remain focused on execution of our core programs, with ROXUS moving toward US commercial launch through SHED and Strive, the final SPONTAN Phase II report expected shortly and planning underway for the pivotal phase III study in 2027."

Testosterone deficiency and erectile dysfunction can present within the same men's health consultation and involve overlapping prescribers and patient-access channels. Mr Rodne said KYZATREX therefore represents a complementary opportunity for LTR Pharma to broaden its Australian men's health portfolio while leveraging the clinical networks, telehealth channels and distribution infrastructure already established through SPONTAN.

"This strategy is being pursued alongside continued execution of LTR Pharma's core ED programs, including preparations for the U.S. commercial launch of ROXUS and planning for the pivotal SPONTAN Phase III study," he said.

LTP shares were steady at 50.5¢, with a market capitalisation of $91.79 million.